Submit manuscript at www.longdom.org/submissions/cancer-research-immuno-oncology.html or send as an e-mail attachment to the Editorial Office at [email protected]
Table of Contents
About the Journal
Journal of Cancer Research and Immuno-Oncology is a fast-developing open access journal in the field of cancer research. It focuses on becoming one of the best peer reviewed journal in the field of cancer research. Journal of Cancer Research and Immuno-Oncology covers a broad scope for the authors to make their valuable contributions in cancer biology, tumor, radiology, metastatis, cancer immunotherapy, oncology, radiation therapy etc
This Journal provides a unique forum dedicated to scientists to express their research articles, review articles, case reports and short communications on any array of latest cancer research and Immuno-Oncology. The Journal of Cancer Research and Immuno-Oncology is a Peer Reviewed Open Access Journal supported by universally prominent Editorial Board members. Abstracts and full texts of all articles published by Journal of Cancer Research and Immuno-Oncology are freely accessible to everyone.
The journal is using Editorial Manager System for quality in review process. Editorial Manager is an online manuscript submission, review and tracking system. Review processing is performed by the editorial board members of Journal of Cancer Research and Immuno-Oncology or outside experts; approval of at least two independent reviewers followed by the editor is required for acceptance of any citable manuscript. Authors may submit manuscripts and track their progress through the system, hopefully to publication. Reviewers can download manuscripts and submit their opinions to the editor. Editors can manage the whole submission/review/revise/publish process.
Current Issue Highlights
The Effects of Checkpoint Blockade and a CD40 Agonist on Tindependent and T-dependent Antibody Responses in Mice: Implications for Optimization of Vaccination Strategies in Patients Receiving Immunotherapies
Karen M Michel, Ashley Gehrand, Michael A Thompson and Martin Oaks